指南与共识呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19患者呼吸支持应用现状的立场文件

Position Paper for the State-of-the-Art Application of Respiratory Support in Patients with COVID-19.
指南 / 共识 · Respiration · 2020-06-19
一句话结论德国呼吸学会立场文件:COVID-19相关急性呼吸衰竭按L型和H型区分呼吸支持,无创支持时需持续监测并随时准备插管。

德国呼吸学会组织专家制定COVID-19急性呼吸衰竭(ARF)的呼吸支持治疗策略。文件提出COVID-19可分为3期,晚期肺损伤与典型ARDS不同,分L型和H型,对应早期和晚期肺损伤,呼吸支持时应考虑此区分。ARF评估应基于室内空气条件下动脉或毛细血管血气分析,并计算氧供。在提供个人防护装备(PPE)的前提下,吸入治疗、经鼻高流量(NHF)、持续气道正压(CPAP)或无创通气(NIV)不增加医务人员感染风险;NHF下高FiO2仍不能完全纠正的低氧血症,在不符合插管标准时可升级至CPAP或NIV。NIV应在ICU或类似环境由有经验人员实施,CPAP/NIV期间需持续监测并随时准备插管,病情进展时无创通气不应延迟插管。

要点

  • COVID-19相关ARF分L型和H型,对应早期和晚期肺损伤,呼吸支持时需考虑此区分。
  • ARF评估基于室内空气条件下动脉或毛细血管血气分析,并计算氧供。
  • 提供PPE前提下,吸入治疗、NHF、CPAP或NIV不增加医务人员感染风险。
  • NHF下高FiO2仍不能完全纠正低氧血症且不符合插管标准时,可升级至CPAP或NIV。
  • CPAP/NIV期间需持续监测并随时准备插管,病情进展时无「不插管」医嘱者不应延迟插管。

适用人群与场景

  • COVID-19合并急性呼吸衰竭(ARF)的患者。
  • 适用于需要呼吸支持的COVID-19患者。

诊断标准与关键阈值

  • COVID-19可分3期;晚期肺损伤分L型和H型,对应早期和晚期肺损伤。
  • ARF评估应基于室内空气条件下动脉或毛细血管血气分析,并计算氧供(由氧饱和度、血红蛋白水平、Hüfner因子校正值和心输出量计算)。

处置流程与药物剂量

  • 提供PPE前提下,可进行吸入治疗、NHF、CPAP或NIV,不增加医务人员感染风险。
  • NHF下高FiO2仍不能完全纠正低氧血症且不符合插管标准时,可升级至CPAP或NIV。
  • NIV应在ICU或类似环境由有经验人员实施。
  • CPAP/NIV期间需持续监测并随时准备插管。
  • CPAP/NIV下ARF进展时,无「不插管」医嘱者不应延迟插管。

红旗征与不能漏的情况

  • CPAP/NIV下患者可快速恶化,需持续监测并随时准备插管。
  • 开放系统或无排气系统可增加可吸入颗粒释放;需打开有创通气系统及气管插管操作与感染风险增加相关。

研究设计与关键结果

  • 德国呼吸学会任命专家制定COVID-19急性呼吸衰竭治疗策略,提出关键立场声明及病理生理观察。

证据类型、等级与局限

  • 指南(立场文件)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对COVID-19相关ARF,呼吸支持时应考虑L型和H型的区分。
  • 不要因恐惧感染而将插管作为首要原因;PPE应具有最高优先级。
  • NHF下低氧血症不能完全纠正时,在不符合插管标准时可升级至CPAP或NIV,但需在ICU或类似环境由有经验人员实施并持续监测。

指南或共识出处

  • 德国呼吸学会(German Respiratory Society)立场文件:COVID-19患者呼吸支持应用现状。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Against the background of the pandemic caused by infection with the SARS-CoV-2 virus, the German Respiratory Society has appointed experts to develop therapy strategies for COVID-19 patients with acute respiratory failure (ARF). Here we present key position statements including observations about the pathophysiology of (ARF). In terms of the pathophysiology of pulmonary infection with SARS-CoV-2, COVID-19 can be divided into 3 phases. Pulmonary damage in advanced COVID-19 often differs from the known changes in acute respiratory distress syndrome (ARDS). Two types (type L and type H) are differentiated, corresponding to early- and late-stage lung damage. This differentiation should be taken into consideration in the respiratory support of ARF. The assessment of the extent of ARF should be based on arterial or capillary blood gas analysis under room air conditions, and it needs to include the calculation of oxygen supply (measured from the variables of oxygen saturation, hemoglobin level, the corrected values of Hüfner's factor, and cardiac output). Aerosols can cause transmission of infectious, virus-laden particles. Open systems or vented systems can increase the release of respirable particles. Procedures in which the invasive ventilation system must be opened and endotracheal intubation carried out are associated with an increased risk of infection. Personal protective equipment (PPE) should have top priority because fear of contagion should not be a primary reason for intubation. Based on the current knowledge, inhalation therapy, nasal high-flow therapy (NHF), continuous positive airway pressure (CPAP), or noninvasive ventilation (NIV) can be performed without an increased risk of infection to staff if PPE is provided. A significant proportion of patients with ARF present with relevant hypoxemia, which often cannot be fully corrected, even with a high inspired oxygen fraction (FiO2) under NHF. In this situation, the oxygen therapy can be escalated to CPAP or NIV when the criteria for endotracheal intubation are not met. In ARF, NIV should be carried out in an intensive care unit or a comparable setting by experienced staff. Under CPAP/NIV, a patient can deteriorate rapidly. For this reason, continuous monitoring and readiness for intubation are to be ensured at all times. If the ARF progresses under CPAP/NIV, intubation should be implemented without delay in patients who do not have a "do not intubate" order.

来源:Respiration,查看原文。版权归原作者所有。

参考来源

  1. Pfeifer M, Ewig S, Voshaar T, et al. Position Paper for the State-of-the-Art Application of Respiratory Support in Patients with COVID-19. Respiration. 2020. PMID: 32564028. doi:10.1159/000509104

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。